Alvotech And STADA Extend Partnership Through AVT03 Biosimilar Candidate Addition
Alvotech And STADA Extend Partnership Through AVT03 Biosimilar Candidate Addition
Alvotech和STADA通過AVT03生物仿製藥候選添加擴展合作關係。
Under the terms of the agreement, Alvotech will be responsible for development and manufacturing at its state-of-the-art facility in Reykjavik, Iceland. STADA will become marketing authorization holder, upon approval of AVT03, and will assume semi-exclusive commercial rights in Europe, including Switzerland and the UK, as well as exclusive commercial rights in selected countries in Central Asia and the Middle East.
根據協議的條款，Alvotech將負責在其位於冰島雷克雅未克的最先進設施中進行開發和製造。在AVT03獲得批准後，STADA將成爲授權持有人，並獲得歐洲（包括瑞士和英國的半獨佔商業權利），以及中亞和中東地區的部分國家的獨佔商業權利。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。